Pill Reduces Intermittent Flare-Ups

Published Online: Friday, April 1, 2005

Children with intermittent asthma flare-ups associated with infection may benefit from taking Singulair (montelukast) to reduce their asthma symptoms. Of the approximately 550 children with intermittent asthma between the ages of 2 and 5 years, 278 participants were given Singulair for 12 months. The participants were given the standard dose of either 4 mg or 5 mg, depending on their age. The remaining participants were given a placebo.

The results of the study showed that the participants taking Singulair had 31.9% fewer asthma exacerbations and 31.6% fewer asthma episodes. The participants receiving the medication needed to take inhaled corticosteroids 40% less, compared with children on placebo. The frequency of oral corticosteroid use was lowered by 17.5% in the oral asthma drug group, compared with the placebo group.

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues